Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYENASDAQ:IRTCNASDAQ:PRCTNASDAQ:SLNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYENational Vision$11.31-0.3%$12.13$9.56▼$20.80$891.04M1.221.59 million shs2.45 million shsIRTCiRhythm Technologies$100.34-5.3%$107.62$55.92▼$128.52$3.15B1.45456,256 shs405,490 shsPRCTPROCEPT BioRobotics$51.23-6.5%$63.77$45.68▼$103.81$2.81B1.05762,637 shs1.43 million shsSLNOSoleno Therapeutics$67.48-6.5%$51.19$36.61▼$74.00$3.09B-2.29670,666 shs1.27 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYENational Vision-0.26%-11.78%-6.84%+3.95%-45.23%IRTCiRhythm Technologies-5.27%-4.44%-6.82%+10.48%-6.66%PRCTPROCEPT BioRobotics-6.48%-14.69%-19.16%-39.23%+10.05%SLNOSoleno Therapeutics-6.49%-6.26%+49.99%+45.24%+61.59%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYENational Vision1.808 of 5 stars2.11.00.03.32.80.00.0IRTCiRhythm Technologies1.8526 of 5 stars3.42.00.00.03.40.00.6PRCTPROCEPT BioRobotics2.5729 of 5 stars3.41.00.00.03.63.30.6SLNOSoleno Therapeutics4.4957 of 5 stars4.61.00.04.63.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYENational Vision 2.17Hold$14.0023.78% UpsideIRTCiRhythm Technologies 2.82Moderate Buy$119.7319.32% UpsidePRCTPROCEPT BioRobotics 2.86Moderate Buy$94.2984.04% UpsideSLNOSoleno Therapeutics 3.22Buy$99.6347.64% UpsideCurrent Analyst Ratings BreakdownLatest EYE, IRTC, SLNO, and PRCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$70.00 ➝ $100.003/28/2025SLNOSoleno TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $81.003/28/2025SLNOSoleno TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$74.00 ➝ $108.003/27/2025SLNOSoleno TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$105.003/27/2025SLNOSoleno TherapeuticsLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $105.003/27/2025SLNOSoleno TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$67.00 ➝ $123.003/27/2025SLNOSoleno TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$72.00 ➝ $102.003/7/2025EYENational VisionCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.003/5/2025SLNOSoleno TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$74.003/3/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $14.003/3/2025SLNOSoleno TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYENational Vision$1.82B0.49$1.61 per share7.03$10.60 per share1.07IRTCiRhythm Technologies$591.84M5.33N/AN/A$6.85 per share14.65PRCTPROCEPT BioRobotics$224.50M12.51N/AN/A$5.56 per share9.21SLNOSoleno TherapeuticsN/AN/AN/AN/A$5.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYENational Vision-$65.90M-$0.36N/A41.893.27-0.81%3.52%1.39%5/6/2025 (Estimated)IRTCiRhythm Technologies-$123.41M-$3.64N/AN/AN/A-19.14%-118.83%-11.34%5/1/2025 (Estimated)PRCTPROCEPT BioRobotics-$105.90M-$1.76N/AN/AN/A-50.07%-38.57%-26.06%5/7/2025 (Estimated)SLNOSoleno Therapeutics-$38.99M-$4.26N/AN/AN/AN/A-61.99%-55.21%5/8/2025 (Estimated)Latest EYE, IRTC, SLNO, and PRCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AIRTCiRhythm Technologies-$0.89N/AN/AN/A$153.39 millionN/A3/5/2025Q4 2024SLNOSoleno Therapeutics-$0.86-$1.27-$0.41-$1.27N/AN/A2/25/2025Q4 2024PRCTPROCEPT BioRobotics-$0.34-$0.35-$0.01-$0.35$66.79 million$68.24 million2/20/2025Q4 2024IRTCiRhythm Technologies-$0.29$0.01+$0.30-$0.04$158.30 million$164.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYENational VisionN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/APRCTPROCEPT BioRoboticsN/AN/AN/AN/AN/ASLNOSoleno TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYENational Vision0.300.570.37IRTCiRhythm Technologies9.006.276.12PRCTPROCEPT BioRobotics0.216.025.07SLNOSoleno TherapeuticsN/A17.2617.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYENational VisionN/AIRTCiRhythm TechnologiesN/APRCTPROCEPT BioRobotics89.46%SLNOSoleno Therapeutics97.42%Insider OwnershipCompanyInsider OwnershipEYENational Vision2.30%IRTCiRhythm Technologies0.68%PRCTPROCEPT BioRobotics17.40%SLNOSoleno Therapeutics12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYENational Vision14,00078.78 million76.94 millionOptionableIRTCiRhythm Technologies1,79031.41 million31.09 millionOptionablePRCTPROCEPT BioRobotics43054.82 million43.10 millionOptionableSLNOSoleno Therapeutics3045.86 million37.81 millionOptionableEYE, IRTC, SLNO, and PRCT HeadlinesRecent News About These CompaniesPatricia C. Hirano Sells 3,782 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) StockApril 4 at 7:23 PM | marketbeat.comHC Wainwright Issues Optimistic Estimate for SLNO EarningsApril 4 at 1:21 AM | americanbankingnews.comSoleno Therapeutics (NASDAQ:SLNO) Shares Down 6.7% After Insider SellingApril 3 at 2:18 PM | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $265,156.02 in StockApril 3 at 5:38 AM | insidertrades.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Down 6.7% on Insider SellingApril 3 at 2:16 AM | americanbankingnews.comWinners and wishers: 8 potential Bay Area drug approvals coming this yearApril 2 at 10:25 AM | bizjournals.comSoleno Therapeutics (NASDAQ:SLNO) Stock Price Expected to Rise, HC Wainwright Analyst SaysApril 2 at 3:02 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Director Matthew Pauls Sells 5,937 SharesApril 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) VP Sells $1,013,664.33 in StockApril 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CFO James H. Mackaness Sells 90,622 SharesApril 1, 2025 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 128,653 Shares of StockApril 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 699,095 SharesApril 1, 2025 | marketbeat.comSoleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume After Analyst UpgradeApril 1, 2025 | marketbeat.comSoleno Therapeutics price target raised to $100 from $70 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.comSoleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $100.00April 1, 2025 | marketbeat.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Purchased by Pictet Asset Management Holding SAApril 1, 2025 | marketbeat.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Director Sells $424,792.35 in StockApril 1, 2025 | insidertrades.comSLNO FY2025 EPS Forecast Reduced by Cantor FitzgeraldApril 1, 2025 | americanbankingnews.comQ1 EPS Forecast for Soleno Therapeutics Decreased by AnalystApril 1, 2025 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Rating of "Buy" by AnalystsMarch 31, 2025 | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Rating of "Buy" from AnalystsMarch 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyOne Must-Buy Stock and One to Avoid as Tariffs Shake the MarketBy Gabriel Osorio-Mazilli | March 9, 2025View One Must-Buy Stock and One to Avoid as Tariffs Shake the MarketAdvanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?By Thomas Hughes | March 18, 2025View Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?Salesforce: The Most Resilient Software Stock for DownturnsBy Thomas Hughes | April 2, 2025View Salesforce: The Most Resilient Software Stock for DownturnsEYE, IRTC, SLNO, and PRCT Company DescriptionsNational Vision NASDAQ:EYE$11.31 -0.03 (-0.26%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$11.32 +0.00 (+0.04%) As of 04/4/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.iRhythm Technologies NASDAQ:IRTC$100.34 -5.58 (-5.27%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$100.42 +0.08 (+0.07%) As of 04/4/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.PROCEPT BioRobotics NASDAQ:PRCT$51.23 -3.55 (-6.48%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$51.24 +0.01 (+0.02%) As of 04/4/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.Soleno Therapeutics NASDAQ:SLNO$67.48 -4.68 (-6.49%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$67.53 +0.05 (+0.07%) As of 04/4/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
